This finding suggests that the epigenetic profile of B-cell lymphoma needs to be taken into consideration for preventing relapses, and additional studies are required to define further epigenetic alterations involved in the onset of resistance to CD19-CAR T cell therapy. Here, CD19 is linked to B-cell non-Hodgkin lymphoma.